The identification of the estrogen receptor and the role it has in the development of most breast cancers has led to the development of endocrine therapies. In this enduring program, the faculty will explore these therapies with regard to clinical usage, efficacy, safety, and administration. This case-based program will allow participants to experience real-life examples of how these therapies may be used for HR+/HER2- metastatic breast cancer and inform learners how to tailor treatment individually and overcome endocrine resistance.

RELEASED DATE: September 12, 2025
EXPIRATION DATE: September 12, 2026